Age-Related Macular Degeneration Epidemiology Analysis and Forecast, 2021-2031

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly (National Eye Institution, 2019). AMD is classified into three stages: early AMD, intermediate AMD, and late AMD. Late AMD is the advanced stage of AMD, which is characterized by the presence of late dry AMD or late wet AMD (van Leeuwen, 2003; Coleman et al., 2008; Korb et al., 2014). According to a meta-analysis study, the pooled prevalence of any AMD was reported to be 8.69% among adults ages 45-85 years, but the country-specific total prevalence of AMD can be as high as 30-40% (Augood et al., 2006; Wong et al., 2014). In addition to the high prevalence of the condition, AMD is also associated with severe disability and has a major impact on the quality of life and emotional well-being of an affected individual (Hassell, 2006).

In 2021, there were 79,030,963 total prevalent cases of AMD in men and women combined, age 50 years and older, in the 7MM. Japan accounted for the majority of these cases with 15,936,633 total prevalent cases, while Spain accounted for the fewest cases with 7,002,545 cases in 2021. The publisher's epidemiologists forecast an increase in the total prevalent cases of AMD to 88,512,609 cases in 2031 in the 7MM at an Annual Growth Rate (AGR) of 1.20% during the forecast period. In 2021, there were 33,658,984 diagnosed prevalent cases of AMD in men and women combined, age 50 years and older, in the 7MM. Italy accounted for the majority of these cases with 6,937,268 cases, while Spain accounted for the fewest cases with 2,680,994 cases in 2021. The diagnosed prevalent cases of AMD will increase to 40,317,447 cases in 2031 at an AGR of 1.98% during the forecast period.

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AMD, each segmented into early AMD and late AMD and broken down by sex and age (50-59 years, 60-69 years, 70-79 years, and 80 years and older). The total and diagnosed prevalent cases of late AMD are further segmented into late dry AMD and late wet AMD. The report also includes the total prevalent cases and diagnosed prevalent cases of geographic atrophy (GA) in these markets. The forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals. In addition, in the case of data scarcity, the publisher's epidemiologists used primary market research (PMR) data wherever necessary.
The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The AMD Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global AMD market.
Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
Understand magnitude of AMD by early AMD and late AMD. Late AMD are further segmented into late dry AMD and late wet AMD.

1 Age-Related Macular Degeneration: Executive Summary

1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 7MM Forecast Methodology
2.4.1 Sources
2.4.2 Forecast Assumptions and Methods
2.4.3 Forecast Assumptions and Methods: Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
2.4.4 Forecast Assumptions and Methods: Total Prevalent Cases of GA
2.4.5 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and GA
2.5 Epidemiological Forecast for AMD (2021-31)
2.5.1 Total Prevalent Cases of AMD
2.5.2 Age-Specific Total Prevalent Cases of AMD
2.5.3 Sex-Specific Total Prevalent Cases of AMD
2.5.4 Total Prevalent Cases of Early AMD
2.5.5 Total Prevalent Cases of Late AMD
2.5.6 Total Prevalent Cases of Late Dry AMD
2.5.7 Total Prevalent Cases of Late Wet AMD
2.5.8 Total Prevalent Cases of GA
2.5.9 Diagnosed Prevalent Cases of AMD
2.5.10 Age-Specific Diagnosed Prevalent Cases of AMD
2.5.11 Sex-Specific Diagnosed Prevalent Cases of AMD
2.5.12 Diagnosed Prevalent Cases of Early AMD
2.5.13 Diagnosed Prevalent Cases of Late AMD
2.5.14 Diagnosed Prevalent Cases of Late Dry AMD
2.5.15 Diagnosed Prevalent Cases of Late Wet AMD
2.5.16 Diagnosed Prevalent Cases of GA
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 COVID-19 Impact
2.6.3 Limitations of the Analysis
2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography
3.2 Primary Research - Prescriber Survey
3.3 About the Authors
3.3.1 Epidemiologist
3.3.2 Reviewers
3.3.3 Global Director of Therapy Analysis and Epidemiology
3.3.4 Global Head and EVP of Healthcare Operations and Strategy

List of Tables

Table 1: Summary of Changes to Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbid Conditions Associated with AMD
Table 4: High-Prescribing Physicians (KOL and non-KOLs) Surveyed, By Country

List of Figures

Figure 1: 7MM, Total Prevalent Cases of AMD, Both Sexes, N, Ages =50 Years, 2021 and 2031
Figure 2: 7MM, Diagnosed Prevalent Cases of AMD, Both Sexes, N, Ages =50 Years, 2021 and 2031
Figure 3: 7MM, Total Prevalence of AMD, Men and Women, Ages =50 Years, %, 2021
Figure 4: 7MM, Diagnosed Prevalence of AMD, Men and Women, Ages =50 Years, 2021
Figure 5: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
Figure 6: 7MM, Sources Used to Forecast the Total Prevalent Cases of GA and Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
Figure 7: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages =50 Years, N, 2021
Figure 8: 7MM, Total Prevalent Cases of AMD by Age, Both Sexes, N, 2021
Figure 9: 7MM, Total Prevalent Cases of AMD, by Sex, Ages =50 Years, N, 2021
Figure 10: 7MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages =50 Years, N, 2021
Figure 11: 7MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages =50 Years, N, 2021
Figure 12: 7MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages =50 Years, N, 2021
Figure 13: 7MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, Ages =50 Years, N, 2021
Figure 14: 7MM, Total Prevalent Cases of GA, Both Sexes, Ages =50 Years, N, 2021
Figure 15: 7MM, Diagnosed Prevalent Cases of AMD, Both Sexes, Ages =50 Years, N, 2021
Figure 16: 7MM, Diagnosed Prevalent Cases of AMD by Age, Both Sexes, N, 2021
Figure 17: 7MM, Diagnosed Prevalent Cases of AMD, by Sex, Ages =50 Years, N, 2021
Figure 18: 7MM, Diagnosed Prevalent Cases of Early AMD, Both Sexes, Ages =50 Years, N, 2021
Figure 19: 7MM, Diagnosed Prevalent Cases of Late AMD, Both Sexes, Ages =50 Years, N, 2021
Figure 20: 7MM, Diagnosed Prevalent Cases of Late Dry AMD, Both Sexes, Ages =50 Years, N, 2021
Figure 21: 7MM, Diagnosed Prevalent Cases of Late Wet AMD, Both Sexes, Ages =50 Years, N, 2021
Figure 22: 7MM, Diagnosed Prevalent Cases of GA, Both Sexes, Ages =50 Years, N, 2021

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3921EUR$3,995USD£3,277GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7843EUR$7,990USD£6,554GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€11764EUR$11,985USD£9,831GBP

Scope

Reasons to Buy

Table of Contents

Related Topics

Related Reports

Wet Age-Related Macular Degeneration (Wet AMD) - Market Insight, Epidemiology and Market Forecast - 2034

Age-Related Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Dry Age-related Macular Degeneration (Dry-AMD) - Pipeline Insight, 2024

Wet Age-Related Macular Degeneration (Wet AMD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Macular Degeneration Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F